MOA: Interferes with bacterial DNA synthesis by inhibiting topoisomerase II ( DNA gyrase) and topoisomerase IV
Drug Label Information | Brands:
Brands of Gemifloxacin in Kenya
Gemiflox®, Popular Pharmaceuticals Ltd.
Gemifloxacin is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
- Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis
- Community-acquired pneumonia (of mild to moderate severity) caused by S. pneumoniae (including multi-drug resistant strains, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae
ADVERSE DRUG REACTIONS
Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects
Both oral and injectable fluoroquinolones are associated with disabling side effects involving tendons, muscles, joints, nerves and the central nervous system
These side effects can occur hours to weeks after exposure to fluoroquinolones and may potentially be permanent
Discontinue the drug immediately and avoid the use of systemic fluoroquinolones in patients who experience any of these serious adverse reactions
Because the risk of these serious side effects generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated UTIs, that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options
For some serious bacterial infections, including anthrax, plague, and bacterial pneumonia among others, the benefits of fluoroquinolones outweigh the risks and it is appropriate for them to remain available as a therapeutic option
Take without regard to meals.